Statement re Sinclair Pharma announces a promotion and a new
appointment
Sinclair Pharma plc announces the promotion of
Paul Phull to Managing Director (Europe) & Executive VP
and the appointment of
Christophe Foucher as General Manager of CS Dermatologie
15 November 2007, Godalming, UK: Sinclair Pharma plc is pleased to
announce the promotion of Paul Phull to Managing Director of
Sinclair's European Sales and Marketing operations, and the
appointment of Christophe Foucher as General Manager of Sinclair's
French sales and marketing operation, CS Dermatologie (CSD). Mr
Foucher will join Sinclair in January 2008.
Mr Foucher comes to Sinclair from the dermatology company Galderma,
where he has held several senior management positions, most recently
General Manager, Italy. He joins the Sinclair Group as part of a
succession plan to support the next period of operational growth. As
part of this plan, Paul Phull will lead Sinclair's European sales and
marketing operations.
Didier Rase, current President and founder of CSD, will leave the
Group to pursue other business interests. Mr Rase has made
significant contributions to the integration of the Company into the
Sinclair Group since its acquisition in April 2006. Mr Rase will
contribute to a smooth handover process by remaining available until
mid 2008.
"The Sinclair Group has reached a critical point in its commercial
development," said Paul Phull. "Our sales presence in five countries
demands strategic, co-ordinated management so that Sinclair can
derive the best returns on these investments and drive towards
reaching critical mass in Europe. I look forward to delivering the
best possible growth of the business."
"I am delighted to be joining Sinclair at this important time for the
business in France," said Christophe Foucher, "The role reflects my
commercial experience in European dermatology very closely. The
French business offers great potential for commercial development,
not only within France but through synergies with our other
territories."
Paul Phull
Mr Phull is an experienced executive in international pharmaceutical
commercialisation, having worked in the healthcare industry for over
20 years. Mr Phull joined Sinclair in 2001 as Manager and then
Director of Business Development, and in 2004 was appointed to the
position of Executive Vice-President, Business Development with
responsibility for Sinclair's global sales and business development
via its marketing partners. Prior to joining Sinclair he held senior
sales, marketing and business development positions at Bristol-Myers
Squibb and Yamanouchi and has been involved in a number of biotech
and healthcare start-up companies. As Managing Director, Europe, Mr
Phull becomes responsible for all Sinclair's international commercial
activities, including Sinclair's own operating companies in Europe
and revenues through global marketing partners.
Christophe Foucher
Mr Foucher has 14 years experience in the pharmaceutical industry and
joins Sinclair as General Manager of its French commercial
operation. In his previous position at Galderma Laboratories he
delivered annual double-digit sales growth over a four year period,
gaining market leadership positions in the company's major
territories. Reimbursement and management teams were a key strategic
focus during this time. Christophe is currently the General Manager
for Italy, prior to this he was the Regional Director for Middle
Europe and worked in Sales & Marketing for 5 years, in Africa,
Morocco and India. Christophe has a doctorate degree in pharmacy and
a diploma in management studies. He is fluent in English, French and
Italian, reflecting Sinclair's commercial presence in Europe.
- ends -
For further information please contact:
Sinclair Pharma plc Tel: +44
(0) 1483 410 600
Dr Michael Flynn, CEO
Jerry Randall, CFO
Zoe McDougall, Director of Communications
Capital MS&L
Annabel O'Connor, Anna Mitchell Tel +44 (0)20
7307 5340
Notes to Editors:
About Sinclair Pharma Plc www.sinclairpharma.com
Sinclair Pharma plc is an international specialty pharmaceutical
company. It has a growing sales and marketing operation that is
already present in France, Italy, UK, Spain and Portugal, and a
complementary marketing partner network that spans more than 80
countries.
Sinclair has proven expertise in acquiring or developing commercially
attractive and undervalued products, registering these products and
bringing them to market within a short timeframe. The company
focuses on niche therapeutic areas and its current portfolio includes
products for dermatological conditions and oral health.
"Safe Harbor" Statement under the US Private Securities Litigation
Reform Act of 1995: Some or all of the statements in this document
that relate to future plans, expectations, events, performances and
the like are forward-looking statements, as defined in the US Private
Securities Litigation Reform Act of 1995. Actual results of events
could differ materially from those described in the forward-looking
statements due to a variety of factors.
---END OF MESSAGE---
